A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
Phase 3CompletedDevelopment Stage
Open-angle Glaucoma, Ocular Hypertension
Open-angle Glaucoma, Ocular Hypertension
Jan 20, 2019 → Apr 4, 2023
About A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL is a phase 3 stage product being developed by Santen Pharmaceutical for Open-angle Glaucoma, Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT03822559. Target conditions include Open-angle Glaucoma, Ocular Hypertension.
What happened to similar drugs?
5 of 18 similar drugs in Open-angle Glaucoma, Ocular Hypertension were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03822559 | Phase 3 | Completed |
Competing Products
20 competing products in Open-angle Glaucoma, Ocular Hypertension